XNASVERA
Market cap2.34bUSD
Jan 10, Last price
37.02USD
1D
-12.25%
1Q
-13.34%
IPO
202.20%
Name
Vera Therapeutics Inc
Chart & Performance
P/E
—
P/S
1,258.98
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
2m
Net income
-96m
L+7.79%
CFO
-92m
L+36.37%
Earnings
May 15, 2025
Profile
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 1,862 | ||||
Cost of revenue | 102,012 | 90,057 | |||
Unusual Expense (Income) | |||||
NOPBT | (100,150) | (90,057) | |||
NOPBT Margin | |||||
Operating Taxes | 1,000 | 1,000 | |||
Tax Rate | |||||
NOPAT | (100,151) | (90,058) | |||
Net income | (95,990) 7.79% | (89,056) 173.10% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 115,000 | 82,117 | |||
BB yield | -17.51% | -15.97% | |||
| Debt | |||||
Debt current | 4,872 | 2,645 | |||
Long-term debt | 55,103 | 35,117 | |||
Deferred revenue | |||||
Other long-term liabilities | 286 | 286 | |||
Net debt | (100,752) | (76,949) | |||
| Cash flow | |||||
Cash from operating activities | (92,181) | (67,596) | |||
CAPEX | (63) | (62) | |||
Cash from investing activities | (39,431) | (70,552) | |||
Cash from financing activities | 133,541 | 101,933 | |||
FCF | (98,019) | (95,231) | |||
| Balance | |||||
Cash | 160,716 | 114,653 | |||
Long term investments | 11 | 58 | |||
Excess cash | 160,634 | 114,711 | |||
Stockholders' equity | (308,807) | (213,308) | |||
Invested Capital | 466,922 | 321,788 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 42,707 | 26,571 | |||
Price | 15.38 -20.52% | 19.35 -27.58% | |||
Market cap | 656,835 27.75% | 514,143 -9.57% | |||
EV | 556,083 | 437,194 | |||
EBITDA | (104,236) | (90,903) | |||
EV/EBITDA | |||||
Interest | 992 | ||||
Interest/NOPBT | |||||